Syntimmune Lands $8,000,000 Series A Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    257 Park Avenue South 15th Floor New York, NY 10010 USA
  • Company Description
    Founded in 2013, Syntimmune is the world’s leader in the biology of the neonatal Fc receptor (FcRn). Helmed by the most recognized experts in its field, Syntimmune is positioned to rapidly advance breakthrough therapies which co-opt this unique target.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Apple Tree Partners
  • Venture Investor
    Baxalta Ventures
  • Venture Investor
    Partners Innovation Fund

Trending on Xconomy